Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.52 |
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856114 | 1.00 | GSK3B (0.52) | GSK3BRBP4HTR3EHTR3BCHRNB2 | |
| SCHEMBL2854175 | 1.00 | GSK3B (0.52) | GSK3BRBP4HTR3EHTR3BCHRNB2 | |
| SCHEMBL13528904 | 1.00 | GSK3B (0.52) | GSK3BRBP4HTR3EHTR3BCHRNB2 | |
| Formic Acid SCHEMBL2857648 | 0.96 | GSK3B (0.48) | GSK3BRBP4HTR3EHTR3BCHRNB2 | |
| Formic Acid SCHEMBL2861542 | 0.96 | GSK3B (0.48) | GSK3BRBP4HTR3EHTR3BCHRNB2 | |
| Formic Acid SCHEMBL2859293 | 0.96 | GSK3B (0.48) | GSK3BRBP4HTR3EHTR3BCHRNB2 | |
| SCHEMBL2851300 | 0.92 | CHRNA7 (0.47) | GSK3BHTR3EHTR3BCHRNB2CHRNA7 | |
| SCHEMBL2851299 | 0.92 | CHRNA7 (0.47) | GSK3BHTR3EHTR3BCHRNB2CHRNA7 | |
| SCHEMBL2855680 | 0.92 | CHRNA7 (0.47) | GSK3BHTR3EHTR3BCHRNB2CHRNA7 | |
| Formic Acid SCHEMBL2864650 | 0.88 | CHRNA7 (0.44) | GSK3BHTR3EHTR3BCHRNB2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828179-B1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AGAINST CNS-RELATED DISEASES | MEMORY PHARM CORP (US) | 2010-01-20 | — | — | EP | claimed |
| US-7625924-B2 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-01 | — | — | US | claimed |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-27 | — | — | US | claimed |
| CN-122080557-A | Room-temperature self-repairing electromagnetic shielding hydrogel composite material and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2023023867-A1 | COMPOUNDS FOR REDUCING CHOLESTEROL AND TREATING LIVER AND KIDNEY DISEASE | MCMASTER UNIVERSITY (CA) | 2023-03-02 | — | — | WO | disclosed |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| CN-114867811-A | Adhesive composition | 住友化学株式会社 | 2022-08-05 | — | — | CN | disclosed |
| CN-114671978-A | Composition for encapsulating organic light emitting diode and organic light emitting diode display | 三星SDI株式会社 | 2022-06-28 | — | — | CN | disclosed |
| CN-110872365-B | Composition for encapsulating organic light emitting diode and organic light emitting diode display | 三星SDI株式会社 | 2022-04-15 | — | — | CN | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200200945-A1 | POLYCARBONATE RESIN LENS AND POLYCARBONATE RESIN COMPOSITION | MITSUI CHEMICALS, INC. (JP) | 2020-06-25 | — | — | US | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20080064037-A1 | RNA-SELECTIVE PROBES FOR LIVE CELL IMAGING OF NUCLEAR STRUCTURE AND FUNCTION | NEW YORK UNIVERSITY (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064037-A1 | RNA-SELECTIVE PROBES FOR LIVE CELL IMAGING OF NUCLEAR STRUCTURE AND FUNCTION | NEW YORK UNIVERSITY (US) | 2008-03-13 | — | — | US | disclosed |
| EP-1828179-A2 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | Memory Pharmaceutical Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | US | disclosed |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006069097-A2 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064037-A1 | RNA-SELECTIVE PROBES FOR LIVE CELL IMAGING OF NUCLEAR STRUCTURE AND FUNCTION | SNRPE, HNRNPUL2, EFTUD2 | GSK3B 4376/4885RBP4 1557/4885HTR3E 3418/4885 |
| US-20090215828-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | GSK3B 76/4885RBP4 4458/4885HTR3E 13/4885 |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | GSK3B 2317/4885RBP4 389/4885HTR3E 3052/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | GSK3B 2317/4885RBP4 389/4885HTR3E 3052/4885 |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA6 | GSK3B 1971/4885RBP4 3263/4885HTR3E 628/4885 |
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | GPR119, IDO2, IDO1 | GSK3B 2512/4885RBP4 2082/4885HTR3E 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.